scroll to top
0

Mobile Menu

Header Layout

EBSCO Auth Banner

Let's find your institution. Click here.

Page title

The Position of Neutrophils-To-Lymphocytes and Lymphocytes-To-Platelets Ratio as Predictive Markers of Progression and Prognosis in Patients with Non-Small Cell Lung Cancer.

  • Academic Journal
  • Minkov P; Trakia University, Stara Zagora, Bulgaria.
    Gulubova M; Department of General and Clinical Pathology, Forensic Medicine and Deontology, Trakia University, Stara Zagora, Bulgaria.
    Chilingirov P; Trakia University, Stara Zagora, Bulgaria.
    Ananiev J; Department of General and Clinical Pathology, Forensic Medicine and Deontology, Trakia University, Stara Zagora, Bulgaria.
  • Open access Macedonian journal of medical sciences [Open Access Maced J Med Sci] 2018 Aug 04; Vol. 6 (8), pp. 1382-1386. Date of Electronic Publication: 2018 Aug 04 (Print Publication: 2018).
  • English
  • Background: Non-small cell lung cancer (NSCLC) is an insidious metastasis condition of the lungs often presenting no symptoms at the onset. Defining markers for quick determination of prognosis is essential for building up a treatment strategy.
    Aim: The aim of this study is to define the role of the Neutrophils-to-Lymphocytes ratio (NLR) and Platelets-to- Lymphocytes ratio (PLR) as biomarkers in patients with NSCLC, according to the stage and prognosis of the disease.
    Methods: We investigated 20 patients with NSCLC. NLR and PLR are calculated and are evaluated according to the presence or absence of metastasis, stage of the disease, histological type and survival rate.
    Results: We found that thirteen of the patients had low NLR, while the rest 7 had high NLR (mean 3.15). By analysing PLR we found that 11 patients have low and 9 have high level of PLR (mean 1.42). After the correlations have been made we discovered that in 90.1% of the patients with low PLR no lymph metastasises were detected, while in 50% of the patients with high PLR lymph metastasises were observed (χ2 = 3.99; P = 0.046). We also discovered that in 84.6% of the patients with low NLR lymph metastases were absent, while in 42.9% with high NLR lymph metastasises were present (χ 2 = 1.83; P = 0.176).
    Conclusion: In conclusion, NLR and PLR were discovered as prominent biomarkers which provide relatively fast determination for prognosis in patients with NSCLC.
Additional Information
Publisher: Scientific Foundation SPIROSKI Country of Publication: North Macedonia NLM ID: 101662294 Publication Model: eCollection Cited Medium: Print ISSN: 1857-9655 (Print) Linking ISSN: 18579655 NLM ISO Abbreviation: Open Access Maced J Med Sci Subsets: PubMed not MEDLINE
Publication: Skopje, Republic of Macedonia : Scientific Foundation SPIROSKI
Original Publication: Skopje, Republic of Macedonia : ID Design Press, [2013]-
Sci Rep. 2016 Mar 04;6:22618. (PMID: 26939789)
Cell Physiol Biochem. 2018;46(4):1595-1605. (PMID: 29694985)
Oncol Lett. 2017 Dec;14(6):6449-6456. (PMID: 29163681)
JAMA. 2003 Oct 22;290(16):2149-58. (PMID: 14570950)
World J Surg Oncol. 2013 May 24;11:112. (PMID: 23705622)
Cell Rep. 2015 Feb 3;10(4):562-73. (PMID: 25620698)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
J Korean Med Sci. 2007 Sep;22 Suppl:S104-8. (PMID: 17923734)
Eur Respir J. 1996 Sep;9(9):1826-30. (PMID: 8880098)
Semin Cancer Biol. 2013 Jun;23(3):190-9. (PMID: 23287459)
Lancet Respir Med. 2013 Sep;1(7):551-63. (PMID: 24461616)
Br J Cancer. 2014 Jul 29;111(3):452-60. (PMID: 24921916)
J Thorac Oncol. 2015 Feb;10(2):280-5. (PMID: 25299234)
Ann Surg Oncol. 2012 Jan;19(1):217-24. (PMID: 21638095)
Science. 2011 Mar 25;331(6024):1565-70. (PMID: 21436444)
Respir Med. 2004 Feb;98(2):93-8. (PMID: 14971870)
Med Oncol. 2010 Jun;27(2):357-62. (PMID: 19381892)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Am J Respir Crit Care Med. 2005 Sep 1;172(5):530-51. (PMID: 15879415)
BMC Cancer. 2017 Dec 21;17(1):882. (PMID: 29268698)
Lung Cancer. 2000 Sep;29(3):169-77. (PMID: 10996419)
Med Oncol. 2013 Mar;30(1):432. (PMID: 23283648)
J Surg Oncol. 2005 Sep 1;91(3):181-4. (PMID: 16118772)
Med Oncol. 2013 Mar;30(1):439. (PMID: 23307251)
Lancet. 2013 Aug 24;382(9893):720-31. (PMID: 23972815)
Thromb Haemost. 2009 Apr;101(4):762-9. (PMID: 19350123)
Chest. 2005 Mar;127(3):978-83. (PMID: 15764785)
Med Oncol. 2010 Dec;27(4):1060-5. (PMID: 19847679)
J Clin Oncol. 2005 Jan 1;23(1):175-83. (PMID: 15625371)
Cancer Lett. 2014 Apr 10;345(2):235-41. (PMID: 23941831)
Cancer Microenviron. 2015 Dec;8(3):125-58. (PMID: 24895166)
CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087)
Br J Cancer. 2013 Jul 23;109(2):416-21. (PMID: 23799847)
Sci Rep. 2015 Jul 24;5:12493. (PMID: 26205001)
Mayo Clin Proc. 2008 May;83(5):584-94. (PMID: 18452692)
Asian Pac J Cancer Prev. 2014;15(6):2651-4. (PMID: 24761879)
Thorac Cancer. 2015 May;6(3):275-87. (PMID: 26273373)
Future Oncol. 2010 Jan;6(1):149-63. (PMID: 20021215)
Asian Pac J Cancer Prev. 2013;14(9):5237-42. (PMID: 24175807)
Lancet. 2009 Aug 1;374(9687):379-86. (PMID: 19632716)
Ann Surg Oncol. 2011 Nov;18(12):3362-9. (PMID: 21547702)
Clinics (Sao Paulo). 2015 Jul;70(7):524-30. (PMID: 26222823)
Cancer Res. 2013 Apr 15;73(8):2381-8. (PMID: 23580578)
Br J Cancer. 2014 Apr 15;110(8):1930-5. (PMID: 24667648)
Respiration. 2004 Mar-Apr;71(2):170-3. (PMID: 15031573)
Ann Thorac Surg. 2007 Dec;84(6):1818-24. (PMID: 18036891)
J Thorac Dis. 2013 Dec;5(6):783-9. (PMID: 24409356)
Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914)
Tumori. 2011 Nov-Dec;97(6):743-8. (PMID: 22322841)
Eur J Respir Dis. 1985 Feb;66(2):141-6. (PMID: 2982631)
J Clin Oncol. 2010 Feb 10;28(5):744-52. (PMID: 20038723)
J Exp Med. 1998 Jul 20;188(2):341-50. (PMID: 9670046)
Keywords: Lung cancer; NLR; PLR; Prognosis
Date Created: 20180831 Latest Revision: 20200929
20220902
PMC6108783
10.3889/oamjms.2018.210
30159061

banner_970x250 (970x250)

sponsored